We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+12.08%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$265M
Cap. Flow
+$241M
Cap. Flow %
19.9%
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
17
Reduced
10
Closed
19

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$162M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
3
ONC
BeOne Medicines Ltd
ONC
+$52.3M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$45.9M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$42.7M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$58.1M
2
MRK icon
Merck
MRK
+$43.6M
3
CBAY
Cymabay Therapeutics
CBAY
+$38.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$34.4M
5
PCVX icon
Vaxcyte
PCVX
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.8B
$151M 12.47%
2,150,000
+2,100,000
+4,200% +$162M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$16.1B
$132M 10.95%
1,100,000
+375,000
+52% +$45.9M
NBIX icon
3
Neurocrine Biosciences
NBIX
$18.4B
$97.9M 8.1%
710,000
-90,000
-11% -$12.3M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$79.4M 6.56%
525,000
-100,000
-16% -$14.3M
GMED icon
5
Globus Medical
GMED
$10.9B
$53.6M 4.44%
1,000,000
+200,000
+25% +$10.8M
SLNO
6
DELISTED
Soleno Therapeutics
SLNO
$53.5M 4.42%
1,250,000
-50,000
-4% -$2.26M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$38.5B
$52.3M 4.33%
350,000
+315,000
+900% +$52.5M
ONC
8
BeOne Medicines Ltd
ONC
$34.3B
$50.8M 4.2%
+325,000
New +$52.3M
NARI
9
DELISTED
Inari Medical, Inc. Common Stock
NARI
$38.4M 3.17%
+800,000
New +$42.7M
APLT
10
DELISTED
Applied Therapeutics
APLT
$34.7M 2.87%
5,110,000
+955,000
+23% +$4.29M
LQDA icon
11
Liquidia Corp
LQDA
$7.72B
$29.5M 2.44%
2,000,000
+975,000
+95% +$13.6M
ALXO icon
12
ALX Oncology
ALXO
$268M
$29.1M 2.41%
2,610,000
+955,000
+58% +$13.4M
AZN icon
13
AstraZeneca
AZN
$267B
$27.1M 2.24%
200,000
+75,000
+60% +$9.93M
QURE icon
14
uniQure
QURE
$2.52B
$24.6M 2.03%
4,725,000
+800,000
+20% +$4.59M
INSM icon
15
Insmed
INSM
$22.6B
$20.3M 1.68%
750,000
-150,000
-17% -$4.2M
ARGX icon
16
argenx
ARGX
$54.6B
$19.7M 1.63%
+50,000
New +$19.4M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.28B
$17.2M 1.42%
400,000
+225,000
+129% +$10.3M
TGTX icon
18
TG Therapeutics
TGTX
$8.4B
$16M 1.32%
+1,050,000
New +$16.7M
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$15.5M 1.28%
+1,100,000
New +$13.7M
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$12B
$15.3M 1.26%
+175,000
New +$15.7M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.9M 1.15%
+350,000
New +$10.3M
SLDB icon
22
Solid Biosciences
SLDB
$785M
$13.8M 1.14%
1,035,000
+1,000,915
+2,937% +$9.37M
DNTH icon
23
Dianthus Therapeutics
DNTH
$5.55B
$13.7M 1.13%
455,000
+320,000
+237% +$6.96M
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$13.2M 1.09%
+225,000
New +$14.3M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.63B
$12.9M 1.07%
+100,000
New +$12.2M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vestal Point Capital held 77 positions worth $1.21B, up 28% from $944M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vestal Point Capital deployed $241M of net new capital in Q1 2024, opening 29 new positions and adding to 17 existing holdings. Its largest new stake was BeOne Medicines Ltd: 325,000 shares worth $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $34.4M trimmed.

  • Vestal Point Capital's largest Q1 2024 buy was BeOne Medicines Ltd: 325,000 shares worth $50.8M.
  • Vestal Point Capital added most to Cytokinetics in Q1 2024, an estimated $162M increase.
  • Vestal Point Capital's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $34.4M.
  • Vestal Point Capital fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $58.1M.
  • Vestal Point Capital's ten largest holdings make up 62% of its $1.21B portfolio in Q1 2024.
  • Vestal Point Capital opened 29 new positions and closed 19 in Q1 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.21B.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.